این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
International Journal of Hematology-Oncology and Stem Cell Research، جلد ۱۲، شماره ۲، صفحات ۸۴-۹۱
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی A Double-Blind, Randomized Comparison Study between Zytux™ vs MabThera® in Treatment of CLL with FCR Regimen: Non-Inferiority Clinical Trial
چکیده انگلیسی مقاله Background: Chronic lymphocytic leukemia (CLL) is characterized by accumulation of B cells in blood, lymphoid tissues and bone marrow. Addition of rituximab to CLL chemotherapy regimens has been associated with improved survival. The aim of this study was to establish efficacy and safety of Zytux™ in comparison to MabThera® in treatment of CLL. Materials and Methods: Seventy CLL patients who met the criteria for entering the study were randomized into two groups (35 patients in each group). Both groups received Fludarabine and Cyclophosphamide plus Rituximab as part of the FCR regimen. Group A was treated with Zytux™, and group B was treated with MabThera®. A non-inferiority margin of 20% for the primary outcome was defined to examine the similarity between Zytux™ and MabThera®. Results: Baseline demographic characteristics showed no statistically significant difference between the two groups. The two treatment groups were comparable in terms of laboratory and clinical findings, cellular index changes and CD (5, 19, 20 and 23) counts during therapy cycles and at the end of the treatment period. Regarding safety results, Zytux™ demonstrated a similar profile of adverse reactions in comparison to MabThera®. Moreover, the overall response rate was 88% and 89% for Zytux™ and MabThera®, respectively (CI -0.17, 0.18). Conclusion: Results showed non-inferiority of Zytux™ in terms of efficacy and adverse events as a biosimilar version of MabThera®.  
کلیدواژه‌های انگلیسی مقاله
نویسندگان مقاله | Gholamreza Toogeh
Thrombosis Hemostasis Research Center, Tehran University of Medical Sciences, Tehran, Iran
 
 Department of Internal Medicine, Hematology and Medical Oncology Ward, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran


| Mohammad Faranoush
Pediatric Growth and Development Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran


| Seyed Mohsen Razavi
Clinic of Hematology and Oncology, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran


| Hassan Jalaeikhoo
AJA Cancer Research Center (ACRC), AJA University of Medical Sciences, Tehran, Iran


| Abolghasem Allahyari
Division of Hematology and Medical Oncology, Emam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran


| Mohammad Reza Ravanbod
Department of Internal Medicine, Persian Gulf Tropical Medicine Research Center, Bushehr University of Medical Sciences, Bushehr, Iran


| Fariba Zarrabi
Thrombosis Hemostasis Research Center, Tehran University of Medical Sciences, Tehran, Iran


| Vahid Fallahazad
Research Department, Mahak’s Pediatric Cancer Treatment and Research Center, Tehran, Iran


| Ehsan Rezaei Darzi
Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran


| Shadi Sadat Alizadeh Fard
School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
نشانی اینترنتی http://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/771
فایل مقاله اشکال در دسترسی به فایل - ./files/site1/rds_journals/78/article-78-1970112.pdf
کد مقاله (doi)
زبان مقاله منتشر شده
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات